Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells

Leukemia. 2009 Mar;23(3):605-7. doi: 10.1038/leu.2008.247. Epub 2008 Sep 11.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dexamethasone / administration & dosage
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Forkhead Transcription Factors / analysis
  • Graft vs Host Disease / mortality
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lenalidomide
  • Lymphocyte Count*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / surgery
  • Salvage Therapy
  • T-Lymphocytes, Regulatory / immunology*
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Thalidomide
  • Dexamethasone
  • Lenalidomide